LINTUZUMAB SATETRAXETAN AC-225
UNII V860J30J9N

Substance Identification & Data

This profile provides standardized clinical and technical data for Lintuzumab Satetraxetan Ac-225, uniquely identified by the FDA Unique Ingredient Identifier (UNII) V860J30J9N.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2209911-94-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

V860J30J9N

CAS Registry Number

2209911-94-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LINTUZUMAB SATETRAXETAN AC-225

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C82414

National Cancer Institute reference terminology for clinical and research data.

INN ID

11089

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lintuzumab Satetraxetan Ac-225. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.